Summit Therapeutics SMMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$189.42M-201% | -$219.17M-258% | -$231.79M-312% | -$565.71M-837% | -$62.91M-44.7% | ||
| $44K+76.0% | $42K+90.9% | $42K+110% | $37K+85.0% | $25K-7.4% | ||
| $72.79M+556% | $111.78M+915% | $130.76M+575% | $478.78M+4,218% | $11.1M+16.7% | ||
| -$122.29M-99.9% | -$101.94M-109% | -$93.08M-207% | -$66.74M-102% | -$61.17M-103% | ||
| $245K-41.9% | $164K+1,071% | $71K+22.4% | $0-100% | $422K+10,450% | ||
| -$238K-100% | -$485.16M— | -$71K+99.9% | $150.81M+175% | $160.11M+706% | ||
| $3.8M-50.5% | $573.82M— | $33.81M-83.4% | $2.22M-98.9% | $7.68M+1,483% | ||
| -$118.75M-211% | —— | —— | $86.35M+363% | $106.66M+1,187% | ||
| -$122.54M-99.0% | -$102.1M-110% | -$93.15M-207% | -$66.74M-102% | -$61.59M-104% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.